Cri Analog PG1 Effectiveness and Safety in Covid-19
Status:
Not yet recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the
intravenous prostaglandin E1 analog in the reduction of mortality and complications of
patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized
clinical trial in the Fundación Santa Fe de Bogota